EGFR Exon 19 Mutation
Associated Genetic Biomarkers
EGFR Exon 19 Mutation is present in 1.75% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, melanoma, small cell lung carcinoma, and poorly differentiated non-small cell lung cancer having the greatest prevalence .
EGFR Exon 19 Mutation serves as an inclusion eligibility criterion in 11 clinical trials, of which 11 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Mutation as an inclusion criterion, 6 are phase 2 (6 open), 4 are phase 3 (4 open), and 1 is phase 4 (1 open).
Trials with EGFR Exon 19 Mutation in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma and lung adenocarcinoma .
Icotinib, atezolizumab, carboplatin, observation, and pemetrexed are the most frequent therapies in trials with EGFR Exon 19 Mutation as an inclusion criteria .
Significance of EGFR Exon 19 Mutation in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR Exon 19 Mutation present in 9.75% of all non-small cell lung carcinoma patients .
EGFR Exon 19 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open), 3 are phase 3 (3 open), and 1 is phase 4 (1 open) .
Lung Adenocarcinoma +
EGFR is altered in 26.09% of lung adenocarcinoma patients with EGFR Exon 19 Mutation present in 11.49% of all lung adenocarcinoma patients .
EGFR Exon 19 Mutation is an inclusion criterion in 3 clinical trials for lung adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Mutation and lung adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.